Larkspur Biosciences is building the next precision immunotherapies to outsmart cancer. Larkspur’s approach targets the unique ways that tumors hijack the immune system by developing precision immunotherapies for molecularly defined patient populations in order to overcome these bottlenecks that allow the tumor to subvert the immune system. We are advancing our first-in-class programs to outsmart the tumor and enable robust and sustained immune responses in colorectal cancer (CRC) and beyond. LarkX, our target discovery platform, leverages tumor genetics and immune phenotypes from patient-derived data to fuel its pipeline and offers the opportunities to address multiple types of cancer. We believe that transformational discoveries are found at the interface between disciplines. With a proven track record of drug discovery and development, our team is passionate about solving hard problems and driven to deliver new medicines to cancer patients with significant unmet needs. At Larkspur, we grow together, building a culture that highly values joy, trust, and courage.